199 related articles for article (PubMed ID: 29114907)
21. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
Nakamura T; Fukunaga M; Nakano T; Kishimoto H; Ito M; Hagino H; Sone T; Taguchi A; Tanaka S; Ohashi M; Ota Y; Shiraki M
Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
[TBL] [Abstract][Full Text] [Related]
22. Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial.
Yang L; Sycheva AV; Black DM; Eastell R
Osteoporos Int; 2013 Jan; 24(1):329-38. PubMed ID: 23128664
[TBL] [Abstract][Full Text] [Related]
23. Annual zoledronic acid for osteoporosis.
BMJ Group
Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
[TBL] [Abstract][Full Text] [Related]
24. Respiratory complications associated with IV zoledronic acid infusion in the treatment of postmenopausal osteoporosis.
Taggart H; Cheng J; Archbold P
Osteoporos Int; 2010 Sep; 21(9):1621-2. PubMed ID: 19813042
[No Abstract] [Full Text] [Related]
25. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.
Ding Y; Zeng JC; Yin F; Zhang CL; Zhang Y; Li SX; Liu X; Zhang C; Xue QY; Lin H; Pei FX
Orthop Surg; 2017 Aug; 9(3):284-289. PubMed ID: 28960821
[TBL] [Abstract][Full Text] [Related]
26. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial.
Greenspan SL; Perera S; Ferchak MA; Nace DA; Resnick NM
JAMA Intern Med; 2015 Jun; 175(6):913-21. PubMed ID: 25867538
[TBL] [Abstract][Full Text] [Related]
28. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis.
Devogelaer JP; Brown JP; Burckhardt P; Meunier PJ; Goemaere S; Lippuner K; Body JJ; Samsioe G; Felsenberg D; Fashola T; Sanna L; Ortmann CE; Trechsel U; Krasnow J; Eriksen EF; Garnero P
Osteoporos Int; 2007 Sep; 18(9):1211-8. PubMed ID: 17516022
[TBL] [Abstract][Full Text] [Related]
29. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
Grbic JT; Landesberg R; Lin SQ; Mesenbrink P; Reid IR; Leung PC; Casas N; Recknor CP; Hua Y; Delmas PD; Eriksen EF;
J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
[TBL] [Abstract][Full Text] [Related]
30. [Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].
Geusens PP; Lems WF
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1445-8. PubMed ID: 17633971
[TBL] [Abstract][Full Text] [Related]
31. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.
Boonen S; Sellmeyer DE; Lippuner K; Orlov-Morozov A; Abrams K; Mesenbrink P; Eriksen EF; Miller PD
Kidney Int; 2008 Sep; 74(5):641-8. PubMed ID: 18509324
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Wang C
Am J Ther; 2017; 24(5):e544-e552. PubMed ID: 26938765
[TBL] [Abstract][Full Text] [Related]
33. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture.
Eriksen EF; Lyles KW; Colón-Emeric CS; Pieper CF; Magaziner JS; Adachi JD; Hyldstrup L; Recknor C; Nordsletten L; Lavecchia C; Hu H; Boonen S; Mesenbrink P
J Bone Miner Res; 2009 Jul; 24(7):1308-13. PubMed ID: 19257818
[TBL] [Abstract][Full Text] [Related]
34. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
[TBL] [Abstract][Full Text] [Related]
35. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
Eastell R; Lang T; Boonen S; Cummings S; Delmas PD; Cauley JA; Horowitz Z; Kerzberg E; Bianchi G; Kendler D; Leung P; Man Z; Mesenbrink P; Eriksen EF; Black DM;
Osteoporos Int; 2010 Jul; 21(7):1277-85. PubMed ID: 19802508
[TBL] [Abstract][Full Text] [Related]
36. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
Hines SL; Mincey B; Dentchev T; Sloan JA; Perez EA; Johnson DB; Schaefer PL; Alberts S; Liu H; Kahanic S; Mazurczak MA; Nikcevich DA; Loprinzi CL
Breast Cancer Res Treat; 2009 Oct; 117(3):603-9. PubMed ID: 19214743
[TBL] [Abstract][Full Text] [Related]
37. The effect of once-yearly zoledronic acid on hip structural and biomechanical properties derived using computed tomography (CT) in Japanese women with osteoporosis.
Ito M; Sone T; Shiraki M; Tanaka S; Irie C; Ota Y; Nakamura T
Bone; 2018 Jan; 106():179-186. PubMed ID: 29033381
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Moriwaki K; Mouri M; Hagino H
Osteoporos Int; 2017 Jun; 28(6):1939-1950. PubMed ID: 28265718
[TBL] [Abstract][Full Text] [Related]
39. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.
Otrock ZK; Azar ST; Shamseddeen WA; Habr D; Inati A; Koussa S; Mahfouz RA; Taher AT
Ann Hematol; 2006 Sep; 85(9):605-9. PubMed ID: 16830143
[TBL] [Abstract][Full Text] [Related]
40. [Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)].
Ringe JD; Nitschmann S
Internist (Berl); 2008 Apr; 49(4):502-4. PubMed ID: 18305914
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
